Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $29.6 million.

  • Artiva Biotherapeutics' Change in Acquisitions & Divestments rose 13889.52% to $29.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.8 million, marking a year-over-year increase of 8265.04%. This contributed to the annual value of $56.4 million for FY2024, which is 11026.12% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Change in Acquisitions & Divestments of $29.6 million as of Q3 2025, which was up 13889.52% from $28.2 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Change in Acquisitions & Divestments high stood at $29.6 million for Q3 2025, and its period low was $12.0 million during Q3 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $18.7 million, with a median of $14.0 million in 2024.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 333.33% in 2024, then surged by 13889.52% in 2025.
  • Artiva Biotherapeutics' Change in Acquisitions & Divestments (Quarter) stood at $12.8 million in 2023, then grew by 8.98% to $14.0 million in 2024, then surged by 112.35% to $29.6 million in 2025.
  • Its last three reported values are $29.6 million in Q3 2025, $28.2 million for Q2 2025, and $29.0 million during Q1 2025.